Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): review decision - August 2015 information

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix A - RPP decision paper - August 2015

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix A - RPP decision paper - August 2015 (PDF 69 KB)

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): review proposal - June 2015 information

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix A - matrix of stakeholders

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix A - matrix of stakeholders (PDF 98 KB)

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix B - GE proposal paper - June 2015

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination 2 information

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination document

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination document (PDF 281 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 254 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the ACD

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): GlaxoSmithKline

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): GlaxoSmithKline (PDF 158 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Roche

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Roche (PDF 422 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Breakthrough Breast Cancer

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Breakthrough Breast Cancer (PDF 245 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Department of Health

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Department of Health (PDF 46 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): HealthCare Improvement Scotland

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): HealthCare Improvement Scotland (PDF 11 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Nursing

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Nursing (PDF 57 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Physicians (joint NCRI, RCR, ACP)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Physicians (joint NCRI, RCR, ACP) (PDF 234 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Cameron information

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appeal  information

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appeal decision

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appeal decision (PDF 187 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Response to inital scrutiny

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Response to inital scrutiny (PDF 86 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Initial scrutiny letter

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Initial scrutiny letter (PDF 81 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Appeal letter received

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Appeal letter received (PDF 197 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): register to attend the appeal information

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination  information

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination document

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination document (PDF 266 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 248 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the ACD

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): GlaxoSmithKline

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): GlaxoSmithKline comments on the ACD

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): GlaxoSmithKline comments on the ACD (PDF 78 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): GlaxoSmithKline comments on executable model

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): GlaxoSmithKline comments on executable model (PDF 66 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Roche

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Roche comments on the ACD

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Roche comments on the ACD (PDF 259 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Roche comments on the AG model

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Roche comments on the AG model (PDF 81 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Nursing

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Nursing (PDF 60 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): NHS Portsmouth

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): NHS Portsmouth (PDF 93 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Department of Health

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Department of Health (PDF 4.3 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Commissioning Support Appraisal Service (CSAS)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Commissioning Support Appraisal Service (CSAS) (PDF 138 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Quality Improvement Scotland (QIS)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Quality Improvement Scotland (QIS) (PDF 62 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Pfizer

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Pfizer (PDF 71 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO) (PDF 85 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): comments on the ACD received from the public through the NICE website

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): comments on the ACD received from the public through the NICE website (PDF 216 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): responses to comments on the economic model by the Assessment Group

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): responses to comments on the economic model by the Assessment Group (PDF 100 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): addendum to assessment report

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appraisal consultation

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appraisal consultation document information

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): evaluation report

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appraisal consultation overview

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appraisal consultation overview (PDF 288 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): assessment report

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): assessment report (PDF 2.05 MB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): assessment report erratum

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): assessment report erratum (PDF 349 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Glaxo Smith Kline

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Glaxo Smith Kline (PDF 272 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Roche

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Roche (PDF 80 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Royal College of Physicians

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Royal College of Physicians (PDF 42 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Department of Health

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Department of Health (PDF 63 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Welsh Assembly Government

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Welsh Assembly Government (PDF 45 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - NHS - Quality Improvement Scotland

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - NHS - Quality Improvement Scotland (PDF 88 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): non-manufacturer submission

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): joint submission from Breast Cancer Care

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): joint submission from Breast Cancer Care (PDF 107 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): submission from the Royal College of Nursing

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): submission from the Royal College of Nursing (PDF 45 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): submission from the Royal College of Physicians

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): submission from the Royal College of Physicians (PDF 193 KB)

Manufacturer submissions (executive summary only)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): submission from Glaxo Smith Kline

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): submission from Glaxo Smith Kline (PDF 84 KB)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): submission from Roche Products

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Equality impact assessment - Guidance development

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): assessment report for consultation

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): final scope

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): final matrix

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): response to consultee and commentator comments on draft scope

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): response to consultee and commentator comments on provisional matrix

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): draft scope for the appraisal 

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): provisional matrix of consultees and commentators for the appraisal